⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SUPN News
Supernus Pharmaceuticals, Inc.
Drug-Resistant Epilepsy Market to Accelerate With Significant CAGR by 2036 as Demand for Advanced Therapies Increases | DelveInsight
prnewswire.com
LIVN
PTC
UCB
XENE
AQST
TAK
BHVN
KNOP
VRTX
SUPN
GSK
SNY
MD
Form 8-K
sec.gov
SUPN
Form 8-K
sec.gov
SUPN
Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com
SUPN
Supernus Pharmaceuticals to Participate in March Investor Conferences
globenewswire.com
SUPN
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
globenewswire.com
SUPN
MGTX
JNJ
ARWR
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026
globenewswire.com
SUPN
Lupin Launches Topiramate Extended-Release Capsules in the United States
prnewswire.com
LUPIN
SUPN
EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan
businesswire.com
SUPN
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference
globenewswire.com
SUPN